FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149915537> ?p ?o ?g. }

• W2149915537 endingPage "4515" @default.
• W2149915537 startingPage "4504" @default.
• W2149915537 abstract "// Fabien Gueugnon 1,2,3 , Pierre-François Cartron 1,2,3,4 , Cedric Charrier 5 , Philippe Bertrand 4,5 , Jean-François Fonteneau 1,2,3 , Marc Gregoire 1,2,3 and Christophe Blanquart 1,2,3,4 1 Inserm, U892, F-44000, Nantes, France 2 CNRS, UMR6299, F-44000, Nantes, France 3 Université Nantes, F-44000, Nantes, France 4 Réseau Epigénétique du Canceropôle Grand Ouest 5 CNRS, UMR7285, Institut de Chimie des Milieux et Matériaux de Poitiers, Université de Poitiers, France Correspondence: Christophe Blanquart1, email: // Keywords : Mesothelioma, lung cancer, chemotherapy and epigenetic Received : April 2, 2014 Accepted : June 1, 2014 Published : June 3, 2014 Abstract Histone deacetylase inhibitors (HDACi) have shown promising antitumor effects on numerous cancer cells including malignant pleural mesothelioma (MPM) and lung adenocarcinoma (ADCA) cells. However, clinical trials using these compounds alone have shown limited efficacy against solid tumors. Therefore, new molecules are being developed and combinations with classical chemotherapeutic drugs are being tested. Here, we have evaluated on three MPM and three lung ADCA cell lines the antitumor potential of four new HDACi compounds, either alone or in combination with cisplatin. These effects were compared with those of vorinostat, an HDACi approved for cancer treatments. First, we characterized the HDAC mRNA expression profiles of tumor cells and showed an increase of the classI/classII HDAC ratio. We then treated cancer cells with these new HDACi and observed a cell-death induction and an increase of HDACi target genes and proteins expression. This was particularly evident for NODH compound (pan-HDACi) which had similar effects at nanomolar concentrations as micromolar concentrations of vorinostat. Interestingly, we observed that the HDACi/cisplatin combination strongly increased cell-death and limited resistance-phenotype emergence as compared with results obtained when the drugs were used alone. These results could be exploited to develop MPM and lung ADCA treatments combining chemotherapeutic approaches." @default.
• W2149915537 created "2016-06-24" @default.
• W2149915537 creator A5030843699 @default.
• W2149915537 creator A5031443339 @default.
• W2149915537 creator A5035855869 @default.
• W2149915537 creator A5036886359 @default.
• W2149915537 creator A5064037216 @default.
• W2149915537 creator A5066392804 @default.
• W2149915537 creator A5070440663 @default.
• W2149915537 date "2014-06-03" @default.
• W2149915537 modified "2023-10-01" @default.
• W2149915537 title "New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells" @default.
• W2149915537 cites W1967018540 @default.
• W2149915537 cites W1968568016 @default.
• W2149915537 cites W1972149587 @default.
• W2149915537 cites W1975592953 @default.
• W2149915537 cites W1988828631 @default.
• W2149915537 cites W2009944379 @default.
• W2149915537 cites W2018252446 @default.
• W2149915537 cites W2018313485 @default.
• W2149915537 cites W2018750602 @default.
• W2149915537 cites W2029148944 @default.
• W2149915537 cites W2038148200 @default.
• W2149915537 cites W2039203273 @default.
• W2149915537 cites W2049674541 @default.
• W2149915537 cites W2050931169 @default.
• W2149915537 cites W2051257692 @default.
• W2149915537 cites W2054240721 @default.
• W2149915537 cites W2054977853 @default.
• W2149915537 cites W2071393652 @default.
• W2149915537 cites W2074974325 @default.
• W2149915537 cites W20935937 @default.
• W2149915537 cites W2096279453 @default.
• W2149915537 cites W2097996513 @default.
• W2149915537 cites W2098796901 @default.
• W2149915537 cites W2102627969 @default.
• W2149915537 cites W2102650381 @default.
• W2149915537 cites W2105779261 @default.
• W2149915537 cites W2115803781 @default.
• W2149915537 cites W2115990145 @default.
• W2149915537 cites W2119816457 @default.
• W2149915537 cites W2120420804 @default.
• W2149915537 cites W2129967236 @default.
• W2149915537 cites W2136870875 @default.
• W2149915537 cites W2147934804 @default.
• W2149915537 cites W2148718757 @default.
• W2149915537 cites W2151222245 @default.
• W2149915537 cites W2154245915 @default.
• W2149915537 cites W2172260980 @default.
• W2149915537 cites W4229637436 @default.
• W2149915537 cites W4296217589 @default.
• W2149915537 doi "https://doi.org/10.18632/oncotarget.2056" @default.
• W2149915537 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4147341" @default.
• W2149915537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24980825" @default.
• W2149915537 hasPublicationYear "2014" @default.
• W2149915537 type Work @default.
• W2149915537 sameAs 2149915537 @default.
• W2149915537 citedByCount "22" @default.
• W2149915537 countsByYear W21499155372014 @default.
• W2149915537 countsByYear W21499155372015 @default.
• W2149915537 countsByYear W21499155372016 @default.
• W2149915537 countsByYear W21499155372017 @default.
• W2149915537 countsByYear W21499155372018 @default.
• W2149915537 countsByYear W21499155372019 @default.
• W2149915537 countsByYear W21499155372022 @default.
• W2149915537 countsByYear W21499155372023 @default.
• W2149915537 crossrefType "journal-article" @default.
• W2149915537 hasAuthorship W2149915537A5030843699 @default.
• W2149915537 hasAuthorship W2149915537A5031443339 @default.
• W2149915537 hasAuthorship W2149915537A5035855869 @default.
• W2149915537 hasAuthorship W2149915537A5036886359 @default.
• W2149915537 hasAuthorship W2149915537A5064037216 @default.
• W2149915537 hasAuthorship W2149915537A5066392804 @default.
• W2149915537 hasAuthorship W2149915537A5070440663 @default.
• W2149915537 hasBestOaLocation W21499155371 @default.
• W2149915537 hasConcept C104317684 @default.
• W2149915537 hasConcept C121608353 @default.
• W2149915537 hasConcept C126322002 @default.
• W2149915537 hasConcept C142724271 @default.
• W2149915537 hasConcept C143998085 @default.
• W2149915537 hasConcept C2776256026 @default.
• W2149915537 hasConcept C2776262904 @default.
• W2149915537 hasConcept C2776694085 @default.
• W2149915537 hasConcept C2777407522 @default.
• W2149915537 hasConcept C2778239845 @default.
• W2149915537 hasConcept C2778305200 @default.
• W2149915537 hasConcept C502942594 @default.
• W2149915537 hasConcept C55493867 @default.
• W2149915537 hasConcept C64927066 @default.
• W2149915537 hasConcept C71924100 @default.
• W2149915537 hasConcept C86803240 @default.
• W2149915537 hasConceptScore W2149915537C104317684 @default.
• W2149915537 hasConceptScore W2149915537C121608353 @default.
• W2149915537 hasConceptScore W2149915537C126322002 @default.
• W2149915537 hasConceptScore W2149915537C142724271 @default.
• W2149915537 hasConceptScore W2149915537C143998085 @default.
• W2149915537 hasConceptScore W2149915537C2776256026 @default.
• W2149915537 hasConceptScore W2149915537C2776262904 @default.

• next